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Abstract 
The effect of ganglioside GM1 on isoproterenol-induced AMP accumulation was studied in insect Sf9 cells expressing the human 
/3t-adrenergic receptor by infection with recombinant baculovirus. When such Sf9 cells were treated with isoproterenol plus IBMX, 
intracellular cAMP formation increased approximately 10-fold over the basal level. Preincubation of the baculovirus-infected cells with 
GM1 for 1 h caused a concentration-dependent inhibition of the isoproterenol-induced AMP accumulation. Phosphatidylserine, GM3, 
GTlb and a bovine brain ganglioside preparation lacking GM1 did not cause significant inhibition. Forskolin-induced cAMP 
accumulation was not affected by the GM1 treatment. Inhibition of isoproterenol-induced AMP formation by GM1 was not observed in 
Sf9 cells expressing fl2-adrenergic receptor instead of the flt-adrenergic receptor. Binding studies with (-)-[3H]CGP12177 showed that 
preincubation with GM1 significantly reduced the affinity of antagonist binding to the /3t-adrenergic receptor. These results suggest that 
GM1 or related ganglioside structure(s) may function as natural modulator(s) of the /3t-adrenergic receptor. 
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I. Introduction 
Gangliosides comprise part of the carbohydrate network 
on the surface of virtually all vertebrate cells, fulfilling 
membrane functions that have yet to be fully characterized 
[1-3]. However, it is becoming increasingly evident that 
gangliosides are able to raodulate a variety of proteins in 
the membrane, leading to either enhancement or down-reg- 
ulation of activity. Proteir s thus affected include enzymes, 
receptors, adhesion molecules, and ion channels [3-5]. 
One of the first demonstrations of enzyme modulation was 
that showing a significant increase in basal adenylyl cy- 
clase activity on addition of mixed brain gangliosides to 
cerebral cortex membranes [6]. A subsequent s udy, on the 
other hand, revealed an inhibitory effect of exogenous 
gangliosides on basal, thyrotropin-induced, and fluoride- 
induced adenylyl cyclase activity of thyroid membranes, 
with the suggestion that the applied gangliosides were 
interacting directly with adenylyl cyclase rather than the 
receptor [7]. This was partially supported by a subsequent 
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report in which gangliosides directly inserted into thyroid 
plasma membranes depressed adenylyl cyclase activity 
through reduced binding of thyrotropin to its receptor as 
well as interaction at post-receptor sites [8]. A more recent 
study with myocytes revealed that GM 1 could increase the 
efficacy of activation of/3-adrenergic receptors (fl-AR) by 
isoproterenol and decrease the threshold concentration of 
isoproterenol needed to increase the open probability of 
maxi-K ÷ channels [9]. Finally, GM1 significantly reduced 
the threshold concentration of opioids required to prolong 
the action potential duration in sensory neurons [10], a 
process postulated to involve allosterically regulated cou- 
pling of the receptor via G s to adenylyl cyclase [11]. 
In this study we have adopted a different approach to 
assess ganglioside modulation of the adenylyl cyclase sys- 
tem, utilizing the baculovirus expression vector to insert 
fl-AR into Spodoptera frugiperda (Sf9) insect cells [12]. 
The fact that insect cells in general appear to lack ganglio- 
sides in their membrane [13] allows for control of ganglio- 
side composition through insertion of exogenous molecules 
and thereby avoids the complication encountered in most 
animal cell studies in which exogenously inserted ganglio- 
side must be considered in conjunction with the endoge- 
2 M. Saito et al./Biochimica et Biophysica Acta 1267 (1995) 1-5 
nous membrane gangliosides. With Sf9 cells expressing 
functionally active /3-adrenergic receptors we have ob- 
served a selective modulatory effect of GM 1. 
2. Materials and methods 
briefly at 3000 RPM, and the supernatants extracted 4 X 
with ether to remove TCA. Cyclic AMP was measured by 
the protein binding method [16]. The TCA precipitates 
were dissolved in 1 M NaOH and portions assayed for 
protein using Coomassie Protein Assay Reagent (Pierce 
Chemicals, Rockford, IL). 
2.1. Materials 2.4. Radioligand binding assay 
Sf9 cells and the recombinant baculovirus for human 
/32-AR were kind gifts of Dr. Stephane Dion. TNM-FH 
medium, (-)-isoproterenol, 3-isobutyl- 1-methylxanthine, 
forskolin, ( - )-propranolol and bovine serum albumin were 
purchased from Sigma. Delipidated fetal bovine serum 
(FBS) was obtained from Cocalico Biologicals (Reams- 
town, PA). Gangliosides GM1, GM3, GTlb and phospha- 
tidylserine were gifts from Fidia Research Laboratories 
(Abano Terme, Italy). (-)-[3H]CGP12177 was obtained 
from Amersham (Arlington Heights, IL). 
2.2. Recombinant viruses and cell culture 
Recombinant infectious baculovirus was generated and 
propagated essentially according to Summers and Smith 
[12]. The coding region of the human /31-adrenergic recep- 
tor from --8 (AccI) to + 1571 (BgllI) [14] was blunted 
using T 4 DNA polymerase and inserted into the blunted 
NheI site of pJVPIOZ (kindly provided by Dr. C.D. 
Richardson). Baculovirus containing the /32-adrenergic re- 
ceptor was prepared as described [15]. The insect cell line 
Sf9 was maintained as a monolayer in 75-cm 2 Falcon 
flasks containing 9 ml of TNM-FH medium and 1 ml of 
delipidated FBS with gentamycin (50 /xg/ml). Incubation 
temperature was 27 ° C. Procedures for cell culture and 
viral infection were carried out as previously described 
[12]. 
2.3. cAMP accumulation experiments 
Sf9 cells were seeded on 6-well (35-mm diam./well) 
Costar cluster plates at a density of approximately 1.2 • 10 6 
cells/well in 1 ml TNM-FH medium containing 10% FBS. 
After 1 h the medium was removed and virus solution (0.5 
ml in the complete medium) was added at a multiplicity of 
infection of approximately one to three. Following incuba- 
tion for 1 h at 27 ° , the inoculum was removed, the cells 
were rinsed with TNM-FH medium and incubated in the 
latter containing 10% delipidated FBS for 2 days. In a 
typical experiment, he infected cells thus obtained were 
rinsed and incubated with or without ganglioside (0.1-100 
/xM) in TNM-FH medium without FBS for 1 h. During the 
final 20 min 100 /zM IBMX was added or not, and the 
cells then treated with 10 /xM (-)-isoproterenol for 15 
min. The cells were quickly rinsed with cold PBS and 0.6 
ml of 0.5% TCA was added to each well. The well 
contents were scraped into separate tubes, centrifuged 
For this assay, Sf9 cells were seeded on 24-well (15-mm 
diam./well) Costar cluster plates and infected with virus 
as described above. Binding of (-)-[3H]CGP12177 to 
intact cells was carried out as described [17]. Briefly, the 
virus-infected Sf9 cells (2.9-105 cells/well) were incu- 
bated in TNM-FH medium with or without 10 p~M GM1 
for 1 h and the cells were rinsed with TNM-FH medium. 
Then 1.25 ml of TNM-FH medium containing 30 /zg 
bovine serum albumin and 0.1-4 nM (-)-[3H]CGP12177 
was added to each well and the cells were incubated at 
27°C for 2 h. The cluster plates were placed on ice and 
washed three times with 1 ml of ice-cold PBS. The cells 
were then dissolved in 0.25 ml of 0.2 M NaOH by 
incubating 15 min at 70 ° C, and aliquots of 100/zl and 50 
/zl were taken for determination f 3H and protein, respec- 
tively. Non-specific binding was determined in the pres- 
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Fig. 1. Effect of GM1 on cAMP formation induced by isoproterenol and 
IBMX. Sf9 cells infected with flI-AR recombinant baculovirus were 
incubated with the indicated concentration f GMl for 40 min, then 100 
p,M 1BMX was added, After 20 rain exposure to IBMX, the cells were 
treated with 10 p,M isoproterenol for 15 min and cAMP contents 
measured as described. Controls (hatched areas) were not treated with 
isoproterenol. Data are mean + S.E,M., n (number of wells) = 3. * P < 
0.05. 
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Fig. 2. Specificity of GM1. The effects of 10 /zM GM1, phosphatidyl- 
serine (PS), GTlb, and bovine brain ganglioside mixture (BBG) from 
which GM1 was removed, on isoproterenol-induced AMP accumulation 
were examined by the method e:scribed in Fig. 1. Data are mean 5: S.E.M., 
n=4or  5. * P <0.05. 
ence of 1 /zM (-)-propranolol. K d and Bma x for ( - ) -  
[ 3 H]CGP 12177 were deten'nined by Scatchard analysis. 
3. Results 
The Sf9 cells which we infected with recombinant 
baculovirus, expressing either /31- or fl2-AR, both medi- 
ated enhanced cAMP formation in the presence of iso- 
proterenol. Isoproterenol failed to cause cAMP accumula- 
tion in uninfected Sf9 cells. Sf9 cells expressing fl2-AR 
Table 1 
Effect of preincubation with various gangliosides on isoproterenol-induced 
cAMP formation 
cAMP: nmol/mg protein/15 rain 
Control 0.99 5= 0.02 
GM1 0.81 -+0.03 a 
BBG-GM 1 0.95 -+ 0.05 
GM3 0.94 4- 0.01 
Sf9 cells infected with fli-AR r,~combinant baculovirus were incubated 
with 10 /zM GM1, bovine brain ganglioside mixture lacking GM1, or 
GM3 for 120 min followed by addition of 100 /xM IBMX. After another 
20 min, the culture medium was removed and the cells rinsed with 
RNM-FH medium and incubated with fresh TNM-FH containing 10 /zM 
isoproterenol and 100/xM IBMX for 15 min. Cyclic-AMP accumulation 
was measured as described. Data are mean-t-S.E.M.; n (no. of wells) = 
6. 
a P < 0.05. 
Table 2 
Effect of GM1 on [H]-CGP12177 binding 
Bma x (pmol/mg) K d (pM) 
Control 1.84 _+ 0.11 207 4- 19 
GM1 1.96_+0.10 406_+52 
Sf9 cells infected with fli-AR recombinant baculovirus were incubated 
with or without 10 /.~M GM1 for 1 h, rinsed and the binding of 
(-)-[H]CGP12177 was performed as described in Section 2. Data are 
mean + S.E.M., from four experiments. 
that were subjected to various concentrations of GM1 
(0.01-100 /zM) and isoproterenol (0.001-100 /xM) 
showed no modulation by ganglioside (not shown), so all 
further experiments were performed with /31-AR. When 
the cells were preincubated with GM1 and IBMX as 
described, isoproterenol-induced AMP accumulation was 
inhibited by 20-37%, depending on GM1 concentration 
(Fig. 1). A similar inhibitory effect was observed without 
IBMX, although the amount of cAMP that accumulated in 
both control and GMl-treated cells was reduced by 50%: 
cAMP formation was inhibited 27.8 ___ 3.7% and 37.4 ___ 
8.6% by 0.1 /xM and 10/xM GM1, respectively; 100 /xM 
GM1 gave essentially the same result as 10 /zM. Ganglio- 
side GTlb and a mixture containing all bovine brain 
gangliosides except GM1 caused only slight (statistically 
insignificant) inhibition while phosphatidylserine had no 
effect (Fig. 2). Specific inhibition induced by GM1 was 
also observed when the cells were preincubated with GM1 
and rinsed with TNM-FH medium before addition of 
isoproterenol (Table l). 
In experiments o determine the locus of GMI action, 
direct stimulation of adenylyl cyclase with forskolin re- 
suited in no GM1 effect (not shown). However, an effect 
at the receptor level was indicated in binding studies with 
the hydrophil ic f l-adrenergic antagonist ( - ) -  
[3H]CGP12177, which bound to /31-AR expressing Sf9 
cells in a dose-dependent manner. The non-specific bind- 
ing determined using (-)-propranolol was less than 15%. 
Table 2 shows the Scatchard analysis data of apparent K d 
and maximum binding. Cells preincubated with 10 ~M 
GMI for 1 h showed increased K d, while the maximum 
binding remained unchanged. Non-specific binding was 
not affected by GM 1 treatment. 
4. Discussion 
Adrenergic receptors are representative of a large fam- 
ily of plasma membrane-localized receptors that induce 
intracellular signal transduction through interaction with 
GTP-binding proteins, fl-ARs mediate catecholamine-in- 
duced elevation of cAMP through interaction with G~, a 
stimulatory G-protein. The original subclassification of 
/3-ARs into /31 (equally responsive to epinephrine and 
norepinephrine) and r2 (much more responsive to 
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epinephrine) [18,19] was recently expanded to include /33 
and possibly other subtypes [20-22]. In keeping with 
suggestions that the lipid environment influences function- 
ing of the /3-AR/cAMP-generating system [23], ganglio- 
sides have been shown to affect adenylyl cyclase and/or 
various receptors that are linked through G-proteins to this 
enzyme [6-11]. 
In view of the fact that /31-AR and fl2-AR showed 
distinct differences in agonist-induced cell surface regula- 
tion [24], it is perhaps not surprising that modulatory 
responses of these two receptor subtypes would differ. In 
the present study fl2-AR was unaffected by ganglioside, 
whereas fll-AR showed negative modulation. A modest 
but reproducible inhibition of isoproterenol-activated 
adenylyl cyclase was observed following incorporation of 
GM1 into Sf9 cells expressing this receptor. In addition to 
specificity for the /31-AR, we also observed lipid speci- 
ficity in that no change in adenylyl cyclase activity oc- 
curred on incubation of the infected cells with GM3, 
GTlb, phosphatidylserine, or a mixture of bovine brain 
gangliosides from which monosialo species (principally 
GM1) were removed. GM1 appeared not to induce recep- 
tor modulation through interaction with agonist since the 
same result was obtained whether or not the excess gan- 
glioside was removed after preincubation. Direct interac- 
tion between GM1 and adenylyl cyclase seemed unlikely 
in view of the failure of incorporated ganglioside to alter 
forskolin-stimulated cAMP formation. Finally, the fact that 
similar % inhibition by GM 1 occurred in the presence or 
absence of IBMX, an inhibiter of cyclic nucleotide phos- 
phodiesterase, suggested that potentiation of the latter was 
not the mechanism in this cellular system. The latter 
experiment was prompted by an earlier report indicating 
that mixed brain gangliosides activate 3',5'-cyclic nu- 
cleotide phosphodiesterase i olated from rat cerebral cor- 
tex [25]. Our tentative conclusion in the present study, 
supported indirectly by the GMl-effected increase in ap- 
parent K d of an antagonist, is that the inhibition induced 
by this ganglioside originates in receptor modification 
which affects in some manner the binding of agonist(s) as 
well as antagonist(s). Our data do not preclude an addi- 
tional effect(s) at a post-receptor site(s), e.g., linkage be- 
tween receptor and G~. 
These results may be compared to those of Partington 
and Daly [6] who observed 50-95% increase in the basal 
adenylyl cyclase activity of rat cerebral cortex membranes 
on treatment with 50 /xM mixed brain gangliosides. Inter- 
estingly, the response to norepinephrine was also potenti- 
ated by the gangliosides in a manner which restored 
consistency to this response, suggesting interaction with 
the receptor. This contrasts with the inhibitory effect of 
gangliosides on adenylyl cyclase of human thyroid mem- 
branes observed by Dacremont et al. [7], which was at- 
tributed to direct action on the enzyme. However, the fact 
that unusually high ganglioside concentrations ( > 250/zM) 
were required raises some doubt as to physiological signif- 
icance. The study of Depauw et al. [8], employing bovine 
thyroid membranes into which individual gangliosides were 
inserted, revealed 23-47% inhibition of the TSH-stimu- 
lated adenylyl cyclase activity by GM1 and other ganglio- 
sides, of which GTlb was the most active. This was 
proposed as due to reduced binding of TSH resulting from 
direct interaction of incorporated ganglioside with the re- 
ceptor, a mechanism similar to that proposed here. The 
study of Depauw et al. [8] also suggested that ganglioside 
may additionally interfere with coupling between the a- 
subunit of G s and the catalytic subunit of adenylyl cyclase. 
That there are advantages to using whole cells as op- 
posed to membranes in studies of this kind is evident in 
the greater sensitivity and selectivity that is potentially 
achievable. An example is the modulatory role of GM 1 in 
excitatory opioid receptors of dorsal root ganglion eurons, 
as seen in the marked decrease in threshold concentration 
of opioids required to prolong the action potential duration 
after bath exposure to as little as 10 nM GM 1 for < 5 min 
[10]. In this system the excitatory receptors are linked 
through Gs to adenylyl cyclase/cAMP-dependent ionic 
conductances [ 11 ]. An earlier study demonstrated nhance- 
ment of serotonin-stimulated cAMP formation in NCB-20 
neuroblastoma hybrid cells following incubation of the 
cells in 0.1-1.0 /xM ganglioside [26]. Specific ganglio- 
sides were shown to produce a 10-fold increase in receptor 
affinity for serotonin, thereby approaching the natural 
affinity of brain serotonin receptors. A further example is 
the ability of GM1 to positively modulate the isoprote- 
renol-activated /3-AR of myocytes with concomitant in- 
crease in the open probability of the maxi-K ÷ channels [9]. 
That GM 1 in the latter study appeared to exert a different 
modulatory effect than observed here may indicate a dif- 
ferent subtype of /3-AR or critical differences in cellular 
milieu. An important advantage of the use of Sf9 insect 
cells in this study was the opportunity they provide for 
controlling ganglioside and /3-AR composition owing to 
the absence of endogenous molecules of both types. How- 
ever, complications can arise with the viral system from 
such factors as variation in receptor density; in that regard, 
although the levels of fll-AR expressed in our Sf9 cells 
were significantly higher than those found in brain, similar 
experiments carried out with one-fifth as much virus indi- 
cated the same GM1 effect (not shown). 
Various gangliosides have been proposed as modulators 
of other kinds of membrane r ceptors besides the G~-linked 
type considered here. The EGF, PDGF and insulin recep- 
tors and their associated tyrosine kinase activities are 
strongly modulated by one or another specific ganglioside 
[27]. An 'allosteric regulator' model was proposed in 
which EGF binding to its receptor is allosterically regu- 
lated in relation to tyrosine phosphorylation through bind- 
ing of ganglioside to a specific site [28]. Recent work has 
indicated that such binding inhibits receptor 
dimerization/oligomerization, thusaccounting for inhibi- 
tion of tyrosine kinase and associated cell proliferation 
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[27,29]. Applying this concept o G~-linked receptors, char- 
acterized by seven membrane spanning peptide regions, it 
is conceivable that membrane-associated gangliosides reg- 
ulate receptor function l:hrough influencing the relative 
orientation of  the membrane-embedded segments. This 
implies the existence of specific binding sites for the 
gangliosides, and suggest~ the possibil ity that such binding 
could affect receptor-G protein interaction as well  as con- 
formational change within the receptor. 
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